Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
The DOI matches its Crossref record; 155 of the 156 references it cites were found in a registry or an index.
Abstract
Much of the biopharmaceutical industry's success over the past 30 years has relied on products derived from Chinese Hamster Ovary (CHO) cell lines. During this time, improvements in mammalian cell cultures have come from cell line development and process optimization suited for large-scale fed-batch processes. Originally developed for high cell densities and sensitive products, perfusion processes have a long history. Driven by high volumetric titers and a small footprint, perfusion-based bioprocess research has regained an interest from academia and industry. The recent pandemic has further highlighted the need for such intensified biomanufacturing options. In this review, we outline the technical history of research in this field as it applies to biologics production in CHO cells. We demonstrate a number of emerging trends in the literature and corroborate these with underlying drivers in the commercial space. From these trends, we speculate that the future of perfusion bioprocesses is bright and that the fields of media optimization, continuous processing, and cell line engineering hold the greatest potential. Aligning in its continuous setup with the demands for Industry 4.0, perfusion biomanufacturing is likely to be a hot topic in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The VCD data of run #3 showed that intermittent perfusion could not elevate the cells density, which is mainly attributed to the nutrient shortage (Pérez-Rodriguez et al., 2020; MacDonald et al., 2021).”
From Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies (2023) · cites this paper as MacDonald et al., 2021
Citations
Cites
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085 · cited 2×
“the first FDA approval of the system in 1986 [2].”
BackgroundProduction of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
GENETICS OF SOMATIC MAMMALIAN CELLS
Puck, T. T., Cieciura, S. J., & Robinson, A. (1958) · The Journal of Experimental Medicine · doi:10.1084/jem.108.6.945 · Cited by 960
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667 · cited 1×
“led to the pursuit of smaller, intensified processes [10].”
BackgroundLewis, N. E., Liu, X., Li, Y., Nagarajan, H., Yerganian, G., O'Brien, E., Bordbar, A., Roth, A. M., Rosenbloom, J., Bian, C., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2624 · Cited by 380
Cell factories for insulin production
Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0141-0 · Cited by 359 · cited 1×
“While some products may be produced in microbial systems [4,5], those requiring a complex assembly or post-translational”
BackgroundDisposable bioreactor for cell culture using wave-induced agitation
Singh, V. (1999) · Cytotechnology · doi:10.1023/a:1008025016272 · Cited by 303 · cited 2×
“Rocking bioreactors are used for suspension cultures and primarily emerged with the invention of the WAVE bioreactor in 1998 [45].”
BackgroundMethodPollock, J., Ho, S. V., & Farid, S. S. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24608 · Cited by 291 · cited 7×
“[9], and studies employing ATFs [9,132], performed bet-”
BackgroundInfluentialO’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277 · cited 1×
“platform of choice for new therapeutics [7,8].”
Research works printed but not linked: 1
- Lee SH, 2002, J Microbiol Biotechnol, 12, 457
Cited by
Progress in fed-batch culture for recombinant protein production in CHO cells
Xu, W., Lin, Y., Mi, C., Pang, J.-Y., & Wang, T. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12342-x · Cited by 134
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 131
“…substantial improvements in CHO cell line development and culture, for example, site-specific integration of expression cassettes into the CHO host genome 261 , host cell line engineering 262 , media optimization 263 , fed batch 264 and high cell density culture, including by perfusion 265 .”
Emerging application of hydrocyclone in biotechnology and food processing
Ji, L., Paul, P., Shanbhag, B. K., Dixon, I., Kuang, S., & He, L. (2022) · Separation and Purification Technology · doi:10.1016/j.seppur.2022.122992 · Cited by 70
Matanguihan, C., & Wu, P. Y. K. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102828 · Cited by 61
Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells
Geng, S., Zhao, X., Zhang, X., Zhang, J., Mi, C., & Wang, T. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13008-6 · Cited by 51
Metadata
- Authors
- MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., Mahler, S., Nielsen, L. K., & Munro, T.
- Affiliations
- The University of Queensland (AU)
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Brisbane, Australia
- Thermo Fisher Scientific, Woolloongabba, Brisbane, Australia
- CSL (Australia) (AU)
- Corresponding author
- Munro, Trent
- ORCID
- Venue
- Critical Reviews in Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2021-11-29
- Volume
- 42
- Issue
- 7
- Pages
- 1099-1115
- ISSN
- 0738-8551 (ISSN-L)
- 1549-7801
- OpenAlex
- W3215495644
- Cited by
- 55
- References
- 156
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 15 · 2023: 10 · 2022: 5
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- Funders
- Australian Research Council
- Novo Nordisk Foundation (NNF10CC1016517, NNF14OC0009473)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Physical Sciences › Chemical Engineering › Fluid Flow and Transfer Processes › Fluid Dynamics and Mixing
- Keywords
- perfusion culture, CHO cells, biopharmaceutical manufacturing, continuous bioprocessing, cell line engineering, culture medium optimization, Industry 4.0
- MeSH terms
- Animals, Biological Products, Cricetulus, Cricetinae, Perfusion, CHO Cells, Bioreactors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications. https://app.cochat.ai/papers/10.1080/07388551.2021.1998821
- The paper
- MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., Mahler, S., Nielsen, L. K., & Munro, T. (2022). Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications. Critical Reviews in Biotechnology. https://doi.org/10.1080/07388551.2021.1998821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.